Results
Zepbound weight loss timeline: what to expect month by month
July 15, 2026 · 2 min read
The short answer
Zepbound weight loss builds gradually. In SURMOUNT-1, the average curve was modest during the early titration months, climbed steadily through the middle of the year, and flattened toward the top dose, reaching roughly 20 to 21% on average by around 72 weeks at 15 mg.
These are trial averages, and individual results vary widely in both directions. The month-by-month figures below are a realistic guide to the shape, not a promise for any one person.
The short version
Zepbound (tirzepatide) does not drop weight in a fast early plunge. In its obesity trial, SURMOUNT-1, the average person lost weight slowly while titrating up, then more steadily through the middle of the year, with the curve gradually flattening as they approached the top dose. By around 72 weeks on the 15 mg dose, the average total loss was roughly 20 to 21%. The pattern matters as much as the endpoint: expecting a steady climb, not an overnight change, is what keeps people on the drug long enough to see the result.
Month-by-month (average, at the higher dose)
| Timepoint | Roughly what the average looked like |
|---|---|
| Month 1 to 2 (titration) | Small, often a few percent; the starter doses are gentle by design |
| Month 3 | Around 5 to 7% on average as doses climb |
| Month 6 | Around 12 to 15% for many at higher doses |
| Month 9 | Around 16 to 18%, the steady middle stretch |
| Month 12 | Around 18 to 20% |
| ~Month 16 to 18 (72 weeks) | Roughly 20 to 21% average, curve flattening near plateau |
These are approximate averages from the trial at the top dose, not precise personal targets. Lower maintenance doses land lower on average, and real people scatter widely around every one of these numbers.
Why it starts slow
The first month or two is mostly titration: the starter doses (2.5 and 5 mg) are meant to introduce the drug gently and limit side effects, not to drive big losses. That is normal and not a sign it is failing. Our Zepbound doses post explains the ladder. The bigger, steadier losses tend to arrive once you reach a therapeutic dose.
Why it levels off later
Weight loss slows as it goes for everyone: as you lose weight, the body needs fewer calories, so the same dose produces smaller further losses. A gradual flattening toward the end of the first year is expected, not a failure. A true, early stall can be a reason to review your dose or tighten habits; our plateau guide covers the difference.
What changes your own curve
Your trajectory depends on your dose and how high you titrate, how consistently you take it, your starting point, and the habits around it (protein to protect muscle, training, sleep, and calorie awareness). None of these replace the drug, but together they decide where in the wide range you land. Tracking your weekly weight next to your dose in DoseLog shows your real curve, which is far more useful than comparing yourself to a trial average.
Questions people ask
How much weight will I lose on Zepbound each month?
On average in the SURMOUNT-1 trial, loss was small during the first month or two of titration, reached roughly 5 to 7% by month 3, around 12 to 15% by month 6, and roughly 20 to 21% by about 72 weeks at the 15 mg dose. Individual results vary widely.
How fast does Zepbound start working?
Appetite changes often begin within the first weeks, but visible weight loss is usually slow at first because the starter doses are gentle. The steadier losses tend to arrive once you reach a therapeutic dose after a couple of months of titration.
Why has my Zepbound weight loss slowed down?
Some slowing is normal: as you lose weight, the body needs fewer calories, so the same dose produces smaller further losses, and the curve flattens near plateau. An early or complete stall can be a reason to review your dose or habits with your prescriber.
Is a Zepbound weight loss chart accurate for me?
A chart shows the average trial trajectory, not your personal result. Real people scatter widely around every average, based on dose, consistency, starting point, and habits. Track your own weekly weight against your dose to see your real curve.
References
- 1.Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. NEJM 2022. Read on NEJM ↗
- 2.Zepbound (tirzepatide) prescribing information: clinical trial weight-loss data. View label on DailyMed ↗
- 3.Reviews of weight-loss trajectory and energy-expenditure adaptation. Find on PubMed ↗
This article is general education, not medical advice. DoseLog is a tracking and reflection tool. Decisions about your medication, dose, and symptoms belong with a licensed clinician.
Keep reading